The role of rapid virological response in effective outcome prediction of antivirus treatment in patients with chronic hepatitis C

Abstract


We have studied the role of rapid virological response in treatment outcome in patients with chronic hepatitis C: dependence between sustained virological response and rapid virological response was revealed. Prognostic meaning of other factors (early virological response, viral load and genotype, age of patients and type of therapy) were analyzed too. It was established, that young age, low viral load, genotype 3a and treating with pegylated interferons and ribavirin are associated with higher rate of sustained virological response. The most important predictors of sustained virological response were rapid and early virological responses.

Full Text

Значение быстрого вирусологического ответа в прогнозировании эффективности противовирусной терапии хронического гепатита С

About the authors

A M Ryumin


References

  1. Jensen D.M. et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-960.
  2. Kamal S.M. et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007; 46: 1732-1740.
  3. Yu M.L. et al. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Transl Res 2006; 148: 120-127.
  4. Yu M.L. et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial Hepatology 2008; 47: 1884-1893.
  5. Dalgard O. et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 1260-1265.
  6. Davis G.L. et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652.
  7. Neumann A.U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107.
  8. Yu M.L. et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-559.
  9. Frenci P. et al. Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-458
  10. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.

Statistics

Views

Abstract - 37

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2011 Ryumin A.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies